NCT05617846 is a clinical trial of Anti-osteoporosis therapy in Limb; Fusion, sponsored by Henan Cancer Hospital.

Who is sponsoring NCT05617846?

NCT05617846 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT05617846?

Interventions in NCT05617846: Anti-osteoporosis therapy.

What condition does NCT05617846 study?

NCT05617846 studies Limb; Fusion, Complication.

Is NCT05617846 still recruiting?

NCT05617846 is currently not yet recruiting. Last updated 18 January 2024.

Last reviewed 2024-01-18 · How we verify

NCT05617846

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of Antiosteoporosis Therapy in Osteolysis

Not yet recruiting Last updated 18 January 2024

What this trial tests

trial testing Anti-osteoporosis therapy in Limb; Fusion in 100 participants. Not yet recruiting.

Timeline

28 December 2024

Primary endpoint
30 November 2032

30 November 2032

Quick facts

Lead sponsor	Henan Cancer Hospital
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	100
Start date	28 December 2024
Primary completion	30 November 2032
Estimated completion	30 November 2032
Sites	1 location across China

Drugs / interventions tested

Anti-osteoporosis therapy

Conditions studied

Limb; Fusion — all drugs for Limb; Fusion →
Complication — all drugs for Complication →

Sponsor

Henan Cancer Hospital

Who can join

Eligibility, any sex, with Limb; Fusion or Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To report the postoperative complications and limb function of patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan Cancer Hospital in the next 10 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05617846 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 18 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617846.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing